Literature DB >> 19352330

The P2Y12 receptor: no active metabolite, no party.

Carlo Patrono1.   

Abstract

Poor responders to clopidogrel have low levels of circulating active metabolite. However, in vitro experiments have shown that blood platelets from poor responders are fully inhibited by the active metabolite of this prodrug. Impaired platelet inhibition reflects inadequate plasma levels of active metabolites, and not differences in platelet P2Y12 receptor function.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19352330     DOI： 10.1038/nrcardio.2009.29

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  9 in total

Review 1.  Clinical implications of clopidogrel resistance.

Authors:  Antonio De Miguel; Borja Ibanez; Juan José Badimón
Journal:  Thromb Haemost       Date:  2008-08       Impact factor: 5.249

2.  Clopidogrel, genetics, and drug responsiveness.

Authors:  Jane E Freedman; Elaine M Hylek
Journal:  N Engl J Med       Date:  2009-01-22       Impact factor: 91.245

3.  Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Carlo Patrono; Colin Baigent; Jack Hirsh; Gerald Roth
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

4.  Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

Authors:  Francesca Santilli; Bianca Rocca; Raimondo De Cristofaro; Stefano Lattanzio; Laura Pietrangelo; Aida Habib; Caterina Pettinella; Antonio Recchiuti; Elisabetta Ferrante; Giovanni Ciabattoni; Giovanni Davì; Carlo Patrono
Journal:  J Am Coll Cardiol       Date:  2009-02-24       Impact factor: 24.094

5.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

6.  Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.

Authors:  David Erlinge; Christoph Varenhorst; Oscar O Braun; Stefan James; Kenneth J Winters; Joseph A Jakubowski; John T Brandt; Atsuhiro Sugidachi; Agneta Siegbahn; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2008-12-09       Impact factor: 24.094

7.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

8.  Individual variations of platelet inhibition after loading doses of clopidogrel.

Authors:  P Järemo; T L Lindahl; S G Fransson; A Richter
Journal:  J Intern Med       Date:  2002-09       Impact factor: 8.989

9.  Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.

Authors:  Lars Wallentin; Christoph Varenhorst; Stefan James; David Erlinge; Oscar O Braun; Joseph A Jakubowski; Atsuhiro Sugidachi; Kenneth J Winters; Agneta Siegbahn
Journal:  Eur Heart J       Date:  2007-11-30       Impact factor: 29.983
  9 in total
  2 in total

Review 1.  Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants.

Authors:  Jean Terrier; Youssef Daali; Pierre Fontana; Chantal Csajka; Jean-Luc Reny
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

2.  Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.

Authors:  Xi-Ling Jiang; Snehal Samant; Joshua P Lewis; Richard B Horenstein; Alan R Shuldiner; Laura M Yerges-Armstrong; Lambertus A Peletier; Lawrence J Lesko; Stephan Schmidt
Journal:  Eur J Pharm Sci       Date:  2015-10-30       Impact factor: 4.384
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.